Of mice and men: divergent risks of teriparatide-induced osteosarcoma

@article{Subbiah2009OfMA,
  title={Of mice and men: divergent risks of teriparatide-induced osteosarcoma},
  author={V. Subbiah and V. Madsen and A. Raymond and R. Benjamin and J. Ludwig},
  journal={Osteoporosis International},
  year={2009},
  volume={21},
  pages={1041-1045}
}
  • V. Subbiah, V. Madsen, +2 authors J. Ludwig
  • Published 2009
  • Medicine
  • Osteoporosis International
  • SummarySince approval by the U.S. Food and Drug Administration (FDA) in December 2002, teriparatide (recombinant 1-34 PTH; Forteo®) has been safely used by more than 430,000 patients. Prior to FDA approval, however, there was concern that teriparatide might increase the risk for patients to develop osteosarcoma, as almost 45% of the rats treated with this drug at the highest-tested dose level developed this aggressive form of bone cancer. Balancing the proven benefits of teriparatide shown by… CONTINUE READING
    138 Citations
    The US Postmarketing Surveillance Study of Adult Osteosarcoma and Teriparatide: Study Design and Findings From the First 7 Years
    • E. Andrews, A. Gilsenan, +4 authors D. Masica
    • Medicine
    • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
    • 2012
    • 194
    Safety of osteoanabolic therapy: A decade of experience
    • 104
    Extremely elevated serum alkaline phosphatase level upon treatment with teriparatide: a case report
    Osteosarcomagenesis: Modeling Cancer Initiation in the Mouse
    • 34
    • PDF
    Teriparatide for osteoporosis: importance of the full course
    • 67
    • PDF
    Teriparatide therapy for severe, refractory osteoradionecrosis of the jaw
    • 6

    References

    SHOWING 1-10 OF 15 REFERENCES
    Teriparatide [Human PTH(1‐34)]: 2.5 Years of Experience on the Use and Safety of the Drug for the Treatment of Osteoporosis
    • A. Tashjian, R. Gagel
    • Medicine
    • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
    • 2006
    • 124
    Bone Neoplasms in F344 Rats Given Teriparatide [rhPTH(1-34)] Are Dependent on Duration of Treatment and Dose
    • 275
    • Highly Influential
    • PDF
    Defining a Noncarcinogenic Dose of Recombinant Human Parathyroid Hormone 1–84 in a 2-Year Study in Fischer 344 Rats
    • 117
    The genetics of radiation-induced and sporadic osteosarcoma: a unifying theory?
    • 7
    Anabolic actions of parathyroid hormone on bone.
    • 678
    Osteogenic sarcoma associated with Paget's disease of bone. A clinicopathologic study of 65 patients
    • 145
    Intermittently Administered Human Parathyroid Hormone(1–34) Treatment Increases Intracortical Bone Turnover and Porosity Without Reducing Bone Strength in the Humerus of Ovariectomized Cynomolgus Monkeys
    • 253
    Cancer Statistics, 2007
    • 7,156
    • PDF